BASF will launch four of the Korean biotech company's new peptides throughout 2021
Chemicals giant BASF has signed an exclusive global supply agreement with Korea-based biotechnology firm Caregen for four of its synthetic cosmetic peptides.
The peptides, which have anti-ageing and anti-pigmentation properties for atopic and acneic-prone skins, will be launched by BASF throughout 2021.
BASF believes the partnership will expand its dermocosmetics portfolio – an especially important segment for Asia-based brands.
“There is robust growth in the dermocosmetics sector globally and especially in Asia, as more consumers desire targeted functionality from cosmetics, in line with the personalisation trend,” said Jeff Huh, Head of Marketing Personal Care Solutions at BASF Asia Pacific.
“By using cosmetic products formulated with these peptides as active ingredients, consumers can have a choice of products with proven efficacy.”
David Hérault, Head of Global Product Development Bio-actives at BASF Care Chemicals, added: “Peptides are widely used as biological actives in different markets. Selecting the most promising peptides from Caregen’s huge portfolio and adapting them to the standards of the cosmetic industry has been a great achievement of our team.”
“Building on Caregen’s functional peptides with high technical and commercial competitiveness and BASF’s expertise in solutions and ingredients which are offered to the global cosmetics market, this agreement has both companies well set up for a long- term cooperation,” said Dr Chung Yong-Ji, CEO of Caregen.
“With the ongoing functional health, food and pharmaceutical product development, Caregen aims to soon become a leading peptide platform company, recognised by global customers.”